Global Genetic Disorders Market, By Indication (CF, DMD, LSD, PNH), Disease Type ('Alzheimer's Disease, Cancer, Cystic Fibrosis, Sickle Cell Anaemia, DMD, Thalassemia, 'Huntington's Disease, Rare Diseases, Others) – Industry Trends and Forecast to 2030.
Genetic Disorders Market Analysis and Size
The incidence of genetic disorders such as Down syndrome is caused by an extra copy of chromosome 21, and occurs in approximately 1 in 700 live births in the United States, Sickle cell anemia, is caused by a mutation in the HBB gene, affects approximately 1 in 365 African Americans and Cystic Fibrosis, is caused by mutations in the CFTR gene, affects approximately 1 in 2,500 to 3,500 Caucasian new-borns every year.
Data Bridge Market Research analyses that the genetic disorders market, which was USD 14,954.67 million in 2022, will reach USD 37,559.50 million by 2030 and is expected to grow a CAGR of 12.2% from 2023 to 2030. ""Alzheimer's Disease" dominates the disease type segment of the Genetic Disorders market owing to the growing cases of the disease in the geriatric population. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Genetic Disorders Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
Indication (CF, DMD, LSD, PNH), Disease Type (Alzheimer's Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, DMD, Thalassemia, Huntington's Disease, Rare Diseases, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa.
|
|
Market Players Covered
|
Amicus Therapeutics, Inc. (U.S.), Alexion Pharmaceuticals, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Vertex Pharmaceuticals Incorporated U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S), Amgen Inc. (U.S.), ELITechGroup (France), GW Pharmaceuticals plc. (U.K.), Pfizer Inc. (U.S.), PerkinElmer Inc (U.S.), AutoGenomics (U.S.), Bio-Rad Laboratories, Inc. (U.S.), BioMarin (U.S.), Sarepta Therapeutics (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Genetic disorders are inherited disorders caused by a change, or mutation in DNA sequence and passed onto the next generation by gene transfer from one generation to the next. They can be life-threatening and progressive, with each disease carrying different symptoms and even very rare and complicated to treat and requiring specialized treatments or therapeutics.
Global Genetic Disorders Market Dynamics
Drivers
- Increasing Prevalence of Genetic Disorders
The rising prevalence rate of genetic diseases and disorders is one of the primary factors boosting the market's growth. For instance, the growing incidence of diabetes in the family history directly boosts the market growth rate. Furthermore, several other genetic diseases such as Edward syndrome, Down syndrome, and Patau syndrome and an increasing geriatric population base susceptible to chronic diseases will rapidly enhance the market growth. Thus, this factor boosts market growth.
- Higher Technological Advancements in Prenatal Genetic Testing
Increasing product design advancements and quality improvement are major parameters that enhance the market's growth. For instance, Avellino Labs announced the launch of AvaGen, the genetic eye test, in the U.S. in 2021. It is designed to help identify a patient's risk of keratoconus and other corneal dystrophies. These initiatives by major market players are anticipated to boost growth. Thus, this factor boosts market growth.
Opportunities
- Increasing Demand for Cell-Free DNA in Maternal Plasma Tests
The cell-free DNA in maternal plasma tests segment is in high demand and is boosting the market growth. It is increasingly being used in identifying the risk of genetic disorders in prenatal care through numerous genetic analyses. Technological advancements now have extended the range of testing to whole-genome sequencing, and they can detect several additional chromosomal anomalies, such as sex chromosomal abnormalities and microdeletions. Thus, this factor is helping in improving the market growth.
- Government Investments for Healthcare Interoperability
The increase in funding by the federal government to drive the adoption of these solutions further influence the market. Additionally, the surge in healthcare expenditure, advancements in healthcare infrastructure, and high demand for expanded care delivery positively affect the bleeding disorders treatment market.
Restraints/Challenges
- Limited Treatment Options
Many genetic disorders currently have no cure, and treatment options are limited to managing symptoms and improving quality of life. This can limit treatment options and reduce patient adherence to therapy.
- High Cost of Treatment
Genetic disorder treatment costs can be expensive, particularly for rare genetic disorders. This can limit access to treatment and create financial burdens for patients and healthcare systems.
This genetic disorders market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the genetic disorders market, contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In 2021, Sanofi collaborated with mRNA therapeutics company, Translate Bio, to develop mRNA vaccines and therapies for genetic diseases, including cystic fibrosis.
- In 2021, Amicus announced that their gene therapy, AT-GAA, received Breakthrough Therapy designation from the FDA for the treatment of Pompe disease. The therapy uses a recombinant adeno-associated virus vector to deliver patients a functional copy of the missing gene.
Global Genetic Disorders Market Scope
The genetic disorders market is segmented on the basis of indication and disease type. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- CF
- DMD
- LSD
- PNH
Disease Type
- Alzheimer's Disease
- Cancer
- Cystic fibrosis
- Sickle Cell Anaemia
- DMD
- Thalassemia
- Huntington's Disease
- Rare Diseases
- Others
Global Genetic Disorders Market Regional Analysis/Insights
The genetic disorders market is analysed and market size insights and trends are provided by country, indication and disease type as referenced above.
The countries covered in the genetic disorders market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the genetic disorders market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having genetic disorders such as Alzheimer's disease, and cystic fibrosis.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for rare and genetic disorders, the large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market-impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Genetic Disorders Market Share Analysis
The genetic disorders market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the genetic disorders market.
Some of the major players operating in the genetic disorders market are:
- Amicus Therapeutics, Inc. (U.S)
- Alexion Pharmaceuticals, Inc. (U.S)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
- Vertex Pharmaceuticals Incorporated U.S)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S)
- Amgen Inc. (U.S)
- ELITechGroup (France)
- GW Pharmaceuticals plc. (U.K)
- Pfizer Inc. (U.S)
- PerkinElmer Inc (U.S)
- AutoGenomics (U.S)
- Bio-Rad Laboratories, Inc. (U.S)
- BioMarin (U.S)
- Sarepta Therapeutics (U.S)
SKU-